Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D326 + D337
- Development stage
- Unknown
- Lead developer
- Chong Kun Dang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
D326 + D337 refers to a combination of two investigational compounds being developed as part of multi-drug regimens for the treatment of hypertension and dyslipidemia. These agents are included in fixed-dose combination therapies such as CKD-386 (which also includes D013) and have been studied in phase III clinical trials for their efficacy and safety in patients with essential hypertension and dyslipidemia. The precise mechanisms of action for D326 and D337 have not been publicly defined, but the drug class is reported as antihypertensive and antihyperlipidaemic. The primary developer is Chong Kun Dang Pharmaceutical, a South Korean pharmaceutical company.
Beyond the preview
Go deeper on D326 + D337.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on D326 + D337.